LCT is US-bound
Tuesday, 29 July, 2008
Auckland's diabetes transplant company Living Cell Technologies [ASX: LCT] has appointed a new CEO based in the US.
The current chief, Dr Paul Tan, will remain CEO of LCT New Zealand and will also take up the role of chief operating officer for the company.
The new CEO is Dr Robert Caspari, an LCT director and former head of Aurogen. He is based in Boulder, Colorado, and will lead development of the company from there. LCT recently listed American depository receipts on the International OTCQX, a market aimed at small to medium publicly listed companies.
Caspari has held positions with several pharma companies including Novo Nordisk, Baxter, Boehringer Mannheim, and Schering-Plough.
LCT plans a clinical trial at the Barbara Davis Centre for Diabetes in Denver next year.
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
